Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism
about
Diabetic nephropathy is resistant to oral L-arginine or L-citrulline supplementationLabel-free quantitative urinary proteomics identifies the arginase pathway as a new player in congenital obstructive nephropathy.Delayed Treatment with a Small Pigment Epithelium Derived Factor (PEDF) Peptide Prevents the Progression of Diabetic Renal InjuryArginase inhibition: a new treatment for preventing progression of established diabetic nephropathyTargeting arginase-II protects mice from high-fat-diet-induced hepatic steatosis through suppression of macrophage inflammation.Genetic Targeting of Arginase-II in Mouse Prevents Renal Oxidative Stress and Inflammation in Diet-Induced Obesity.Supplementation with Phycocyanobilin, Citrulline, Taurine, and Supranutritional Doses of Folic Acid and Biotin-Potential for Preventing or Slowing the Progression of Diabetic Complications.Nitric oxide in the normal kidney and in patients with diabetic nephropathy.Pharmacokinetics and Pharmacodynamics of Promising Arginase Inhibitors.Macrophage-derived tumor necrosis factor-α mediates diabetic renal injury.Arginase-2 mediates renal ischemia-reperfusion injury.Distinct roles of arginases 1 and 2 in diabetic nephropathy.Podocyte-specific chemokine (C-C motif) receptor 2 overexpression mediates diabetic renal injury in mice.Serum asymmetric dimethylarginine and arginine levels predict microvascular and macrovascular complications in type 2 diabetes mellitus.Mechanisms of Diabetes-Induced Endothelial Cell Senescence: Role of Arginase 1.
P2860
Q34627559-3ADD3E5A-B097-46C7-A509-F95E666D49DDQ34634938-1620AAA8-F525-4E7F-9AD0-EFAE8AD27CF6Q35710293-798C5AE4-9994-42F3-9F13-8AB2C41A6160Q36017619-9D472A61-F1B5-49C1-9F46-DA81F67FE2C0Q36548517-DD59AB73-02BD-4032-8EA5-EECA6098F841Q37428427-67714536-6AB9-4B59-B498-3B7CE9FCFB32Q37728038-A42E7828-A7ED-4A28-A0A9-7109B49F3033Q38248725-D6B9E70D-DECF-4DA1-94AE-0BDE8D5F187BQ38979298-CE62B227-A634-406B-AFF3-866F8413DEC9Q41559116-965553F9-2EF6-45F5-A402-FAAA3437E73BQ50996032-CF9540DE-032E-4BEF-B051-5EEBA7F0C749Q51033386-31613229-5A3D-45EC-B99A-19C6352EA2F3Q51287276-C550F6CD-8A4E-41D7-A078-13C768E526D8Q53064414-43C89CEF-BADB-4D7E-8C93-401209598AF2Q55153776-B9B4FCF4-DBB2-4A3C-ADB2-1BA1FFDA147C
P2860
Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Arginase inhibition mediates r ...... synthase 3-dependent mechanism
@en
Arginase inhibition mediates r ...... ynthase 3-dependent mechanism.
@nl
type
label
Arginase inhibition mediates r ...... synthase 3-dependent mechanism
@en
Arginase inhibition mediates r ...... ynthase 3-dependent mechanism.
@nl
prefLabel
Arginase inhibition mediates r ...... synthase 3-dependent mechanism
@en
Arginase inhibition mediates r ...... ynthase 3-dependent mechanism.
@nl
P2093
P2860
P356
P1433
P1476
Arginase inhibition mediates r ...... synthase 3-dependent mechanism
@en
P2093
Alaa S Awad
Hanning You
Sidney M Morris
Timothy K Cooper
P2860
P2888
P304
P356
10.1038/KI.2013.215
P407
P577
2013-06-12T00:00:00Z